{"schema_version":"secwatch.filing_event.v1","accession":"0001701541-22-000034","form_type":"8-K","ticker":"BDTX","cik":"0001701541","company_name":"Black Diamond Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.754292+00:00","generated_at":"2026-06-22T04:00:34.106713+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Black Diamond Q3 2022 net loss $21.7M; cash $144.2M into Q3 2024","bullets":["Net loss $21.7M vs $35.1M YoY; R&D expenses fell to $15.8M from $27.6M.","Cash, equivalents & investments $144.2M at Sep 30, 2022, vs $209.8M Dec 31, 2021.","Net cash used in operations $16.5M for Q3 vs $26.5M a year ago; runway through Q3 2024.","BDTX-1535 clinical update expected in 2023; IND for BDTX-4933 planned H1 2023.","Appointed Melanie Morrison as SVP Development Operations in October 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001701541-22-000034","json":"https://secwatch.observer/filing/0001701541-22-000034.json","markdown":"https://secwatch.observer/filing/0001701541-22-000034.md","text":"https://secwatch.observer/filing/0001701541-22-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701541/000170154122000034/0001701541-22-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701541/000170154122000034/bdtx-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:00:34.106713+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19307c88a4b6ffa4e408bdd22f0cf48e823653e2","claim":"Black Diamond Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"Black Diamond Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701541/000170154122000034/0001701541-22-000034-index.htm","confidence":0.6,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}